Please assess the completion status of the following clinical trial:

Trial Title: Irradiated Donor Lymphocytes and Rituximab in Treating Patients With Relapsed or Refractory Lymphoproliferative Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed lymphoproliferative disease~  * CD20-positive disease~* Bidimensionally measurable disease OR abnormal cells detected in blood~* Resistant or refractory to standard therapies and/or unlikely to benefit from additional standard therapies\* AND meets 1 of the following criteria:~  * Disease with anticipated response rate \< 20% after treatment with rituximab alone, including any of the following:~    * Diffuse large cell lymphoma~   * B-cell lymphoblastic lymphoma~   * Burkitt's lymphoma~   * Acute lymphocytic leukemia~ * Relapsed or progressive disease after prior treatment with rituximab, including any of the following:~    * Hodgkin's lymphoma~   * Hairy cell leukemia~   * Chronic lymphocytic leukemia/small lymphocytic lymphoma meeting any of the following criteria:~      * Received prior fludarabine phosphate-containing regimens and relapsed within 1 year of treatment OR ineligible to receive such therapy due to comorbidities or allergies~     * Received prior anti-CD52 monoclonal antibody therapy and relapsed within 1 year of treatment OR ineligible to receive such therapy (for patients without symptomatic lymphadenopathy)~     * Has documentation of disease-associated symptoms, rapid disease progression, or other indications for treatment~   * B-cell prolymphocytic leukemia meeting any of the following criteria:~      * Received prior fludarabine phosphate- or alkylating agent-containing regimens and relapsed within 1 year of treatment OR ineligible to receive such therapy due to comorbidities or allergies~     * Received prior anti-CD52 monoclonal antibody therapy OR ineligible to receive such therapy (for patients without symptomatic lymphadenopathy)~   * Lymphoplasmacytic lymphoma, marginal zone lymphoma, mucosa-associated lymphoid tissue lymphoma, or follicular lymphoma meeting any of the following criteria:~      * Received prior fludarabine phosphate- and/or alkylating agent-containing regimens and relapsed within 1 year of treatment OR ineligible to receive such therapy due to comorbidities or allergies~     * Received prior anti-CD20 monoclonal antibody therapy and relapsed within 1 year of treatment OR ineligible to receive such therapy~     * Received prior radioconjugated anti-CD20 monoclonal antibody therapy OR ineligible to receive such therapy~     * Has documentation of disease-associated symptoms, rapid disease progression, or other indications for treatment~   * Multiple myeloma meeting any of the following criteria:~      * Received prior alkylating agent-, thalidomide-, corticosteroid-, or bortezomib-containing regimens and relapsed after 1 year of treatment OR ineligible to receive such therapies due to comorbidities or allergies~     * Received prior high-dose chemotherapy followed by autologous hematopoietic stem cell rescue and relapsed after treatment OR ineligible to receive such therapy~   * Mantle cell lymphoma meeting the following criteria:~      * Received prior combination chemotherapy and anti-CD20 monoclonal antibody therapy and relapsed after treatment OR ineligible to receive such therapy~   * Diffuse large B-cell lymphoma meeting any of the following criteria:~      * Received prior combination chemotherapy and relapsed after treatment OR ineligible to receive such therapy~     * Received prior salvage combination chemotherapy with or without high-dose chemotherapy followed by autologous hematopoietic stem cell rescue and relapsed after treatment OR not a candidate to receive such therapy~     * Received prior radiolabeled anti-CD20 monoclonal antibody therapy for transformed large cell lymphoma OR ineligible to receive such therapy~   * Burkitt's lymphoma meeting any of the following criteria:~      * Received prior combination chemotherapy and relapsed after treatment OR ineligible to receive such therapy~     * Received prior salvage combination chemotherapy with or without high-dose chemotherapy followed by autologous hematopoietic stem cell rescue and relapsed after treatment OR ineligible to receive such therapy~   * Lymphomatoid granulomatosis meeting any of the following criteria:~      * Received prior single-agent or combination chemotherapy and relapsed after treatment OR ineligible to receive such therapy~     * Has documentation of disease-associated symptoms, rapid disease progression, or other indications for treatment~   * Acute lymphocytic leukemia meeting any of the following criteria:~      * Received prior multi-agent combination chemotherapy administered in sequential induction, consolidation, and maintenance courses and relapsed during or after treatment OR ineligible to receive such therapy~     * Received prior chemotherapy with or without radiotherapy followed by allogeneic hematopoietic stem cell transplantation (HSCT) and relapsed after treatment OR not a candidate for such therapy~     * Received prior treatment with chemotherapy with or without radiotherapy followed by allogeneic HSCT and relapsed after treatment (or not a candidate for such therapy) AND demonstrates persistent cytogenetic, fluorescent in situ hybridization, or molecular (reverse transcriptase-polymerase chain reaction) evidence of the bcr-abl fusion gene despite 6 weeks of treatment with imatinib mesylate NOTE: \*Not eligible to receive standard available salvage regimens anticipated to result in durable remission~* No active CNS malignancy~* Not considered a candidate for allogeneic HSCT~* HLA-partially matched (≥ 2/6) related donor available~PATIENT CHARACTERISTICS:~* ECOG performance status 0-1~* Life expectancy \> 3 months~* Not pregnant~* Negative pregnancy test~* Fertile women must use effective contraception~* Bilirubin \< 1.5 times upper limit of normal (ULN)~* AST \< 3.0 times ULN~* Cardiac ejection fraction \> 35%~* Absolute neutrophil count \> 1,000/mm³ (without cytokines)~* Platelet count \> 50,000/mm³ (untransfused)~* No significant organ dysfunction~* No active uncontrolled infections~* No hypersensitivity reaction to rituximab that has precluded completion of a 4-week course of rituximab therapy~* No uncontrolled psychiatric illness or medical condition that would preclude tolerance of study treatment~PRIOR CONCURRENT THERAPY:~* See Disease Characteristics~* Recovered from prior therapy for at least 7 days~* More than 30 days since prior cytotoxic chemotherapy~* At least 14 days since prior steroids~* At least 14 days since prior radiotherapy to non-target lesions

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Therapeutic allogeneic lymphocytes with rituximab (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).